clinical trial · NCT05404542
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
Cerevel Therapeutics, LLC·phase1·completed·n = 14
Renal ImpairmentTavapadon
brief summary
The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.
started
May 10, 2022
primary completion
Aug 14, 2023
completion
Aug 14, 2023
last updated
Apr 2, 2024
official title
A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following Single Dose of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol